Mumbai, June 22 -- The transaction, valued at $250 million on a cash-free, debt-free basis, including normalized working capital, is expected to be completed before the end of June 2026.

Lannett, a Pennsylvania-based generic pharmaceutical company, focuses on the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition is expected to significantly strengthen Aurobindo USA's presence in this segment while adding a U.S.-based manufacturing facility to its operations.

The deal includes Lannett's manufacturing facility in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA's domestic manufacturing footp...